Hypoxia stimulates tumor angiogenesis by inducing the expression of angiogenic molecules. The negative regulators of this process, however, are not well understood. Here, we report that hypoxia induced the expression of insulin-like growth factor binding protein-6 (IGFBP-6), a tumor repressor, in human and rodent vascular endothelial cells (VECs) via a hypoxia-inducible factor (HIF)-mediated mechanism. Addition of human IGFBP-6 to cultured human VECs inhibited angiogenesis in vitro. An IGFBP-6 mutant with at least 10,000-fold lower binding affinity for IGFs was an equally potent inhibitor of angiogenesis, suggesting that this action of IGFBP-6 is IGF-independent. The functional relationship between IGFBP-6 and vascular endothelial growth factor (VEGF), a major hypoxia-inducible angiogenic molecule, was examined. While VEGF alone increased angiogenesis in vitro, co-incubation with IGFBP-6 abolished VEGF-stimulated angiogenesis. The in vivo role of IGFBP-6 in angiogenesis was tested in flk1:GFP zebrafish embryos, which exhibit green fluorescence protein in developing vascular endothelium, permitting visualization of developing blood vessels. Injection of human IGFBP-6 mRNA reduced the number of embryonic inter-segmental blood vessels by~40%. This anti-angiogenic activity is conserved in zebrafish because expression of zebrafish IGFBP-6b had similar effects. To determine the anti-angiogenic effect of IGFBP-6 in a tumor model, human Rh30 rhabdomyosarcoma cells stably transfected with IGFBP-6 were inoculated into athymic BALB/c nude mice. Vessel density was 52% lower in IGFBP-6-transfected xenografts than in vector control xenografts. These results suggest that the expression of IGFBP-6 in VECs is up-regulated by hypoxia and IGFBP-6 inhibits angiogenesis in vitro and in vivo.
Hypoxia stimulates tumor angiogenesis by inducing the expression of angiogenic molecules. The negative regulators of this process, however, are not well understood. Here, we report that hypoxia induced the expression of insulin-like growth factor binding protein-6 (IGFBP-6), a tumor repressor, in human and rodent vascular endothelial cells (VECs) via a hypoxia-inducible factor (HIF)-mediated mechanism. Addition of human IGFBP-6 to cultured human VECs inhibited angiogenesis in vitro. An IGFBP-6 mutant with at least 10,000-fold lower binding affinity for IGFs was an equally potent inhibitor of angiogenesis, suggesting that this action of IGFBP-6 is IGF-independent. The functional relationship between IGFBP-6 and vascular endothelial growth factor (VEGF), a major hypoxia-inducible angiogenic molecule, was examined. While VEGF alone increased angiogenesis in vitro, co-incubation with IGFBP-6 abolished VEGF-stimulated angiogenesis. The in vivo role of IGFBP-6 in angiogenesis was tested in flk1:GFP zebrafish embryos, which exhibit green fluorescence protein in developing vascular endothelium, permitting visualization of developing blood vessels. Injection of human IGFBP-6 mRNA reduced the number of embryonic inter-segmental blood vessels by~40%. This anti-angiogenic activity is conserved in zebrafish because expression of zebrafish IGFBP-6b had similar effects. To determine the anti-angiogenic effect of IGFBP-6 in a tumor model, human Rh30 rhabdomyosarcoma cells stably transfected with IGFBP-6 were inoculated into athymic BALB/c nude mice. Vessel density was 52% lower in IGFBP-6-transfected xenografts than in vector control xenografts. These results suggest that the expression of IGFBP-6 in VECs is up-regulated by hypoxia and IGFBP-6 inhibits angiogenesis in vitro and in vivo.
Hypoxia is widely recognized as an important driving force for tumor angiogenesis. As tumors grow, the original vasculature becomes insufficient to supply oxygen to the growing tumor cells, and local hypoxia develops. Hypoxia stimulates new blood vessel formation via the induction of angiogenic factors. This neovascularization is critical for tumor progression as it provides tumor cells with oxygen, nutrients and growth factors. [1] [2] [3] A key player in the hypoxia response is hypoxia-inducible factor-1 (HIF-1), which is a heterodimeric transcription factor composed of HIF-1a and HIF-1b. While HIF-1b (also known as ARNT) is constitutively expressed, HIF-1a is sensitive to O 2 tension. When O 2 levels are high, HIF-1a is hydroxylated by prolyl hydroxylase domain-containing proteins (PHDs), then ubiquitinated and targeted for proteosomal degradation. In hypoxic conditions, HIF-1a hydroxylation is inhibited, and it enters the nucleus where it forms a dimer with HIF-1b. The dimerized HIF-1 complex binds to hypoxia response elements (HREs) of its target genes and promotes their transcription. HREs are present in many angiogenic genes including vascular endothelial growth factor (VEGF), a major angiogenic gene, and its receptor, Flk1. 4, 5 Recent studies suggest that there are also negative feedback mechanisms that inhibit angiogenesis during prolonged hypoxia. 6 An et al. 7 reported that expression of RGC32, which inhibits VEGF-and hypoxia-induced angiogenesis, is up-regulated by hypoxia. Similarly, hypoxia induces the expression of GRS5, which inhibits VEGF-induced angiogenesis through p38 MAPK, via HIF-1 activation. 8 Compared to our relatively comprehensive understanding of the induction of angiogenic genes by hypoxia/HIF-1, however, the negative regulators in hypoxia-induced tumor angiogenesis are not well understood.
Insulin-like growth factor binding proteins (IGFBP) 1-6 bind IGFs with high affinity in extracellular fluids and regulate IGF actions at target tissues. 9 Some IGFBPs also possess distinct biological actions that are independent of IGFs.
9 IGFBP-6 is unique among the six IGFBPs because of its 50-fold greater affinity for IGF-II, making it a relatively specific inhibitor of IGF-II actions. 10 Recent studies suggest that IGFBP-6 is a tumor suppressor that inhibits the growth of a number of IGF-II-dependent tumors. 10 In addition to its ability to bind and sequester IGF-II, recent in vitro studies suggest that IGFBP-6 also has IGF-independent actions. 11 An early report showed that hypoxia increased IGFBP-6 mRNA levels in bovine endothelial cells, 12 but expression of IGFBP-6 and its relationship to hypoxia have not been studied in human endothelial cells. More importantly, the role of IGFBP-6 in normal and tumor angiogenesis, if any, is unknown. The objective of our study was therefore to test the hypothesis that hypoxia induces IGFBP-6 gene expression in vascular tissues, and that this induction of IGFBP-6 negatively regulates hypoxia-induced tumor angiogenesis.
Material and Methods

Experimental animals
Wild type and flk1:GFP transgenic zebrafish (Danio rerio) were kept at 28 C under a 14:10-h light-dark photoperiod and fed twice daily. Embryos were obtained from natural breeding and were kept at 28.5 C in embryo-rearing solution supplemented with 0.003% (weight/volume) 2-phenylthiourea (Sigma, St. Louis, MO). 13 All experiments with zebrafish were conducted at Ocean University of China with approved protocols. Female athymic BALB/c nude mice were obtained from the Animal Resource Centre, Western Australia. Xenografting studies were performed at the University of Melbourne in accordance with institutional guidelines of the University of Melbourne and Austin and Repatriation Medical Centre Animal Ethics and Biosafety Committees.
Cell culture and hypoxia treatment
Human umbilical vein endothelial cells (HUVECs) and rat brain vessel endothelial cells were obtained from ATCC and maintained in 45% a-MEM (Gibco) supplemented with 45% F-10 (Gibco), 10% fetal bovine serum (FBS), 100 U/mL penicillin and 100lg/mL streptomycin. Normoxic cells (20% O 2 ) were maintained in a humidified-air atmosphere incubator containing 95% air/5% CO 2 at 37 C. Hypoxic cells (0.1% or 1% O 2 ) were maintained in a controlled atmosphere chamber at 37 C. Rh30 human rhabdomyosarcoma cells were stably transfected with an empty vector or human IGFBP-6 expression plasmids and cultured using published protocols. 14 
Western immunoblotting
Nuclear extracts from cultured HUVECs were prepared following previously published procedure. 15 Western immunoblotting analysis was carried out as reported 16 using a polyclonal anti HIF-1a antibody (Novus Biologicals LLC, Littleton, CO) at a dilution of 1:500. The second antibody used was a goat anti-rabbit antibody (Kang Chen Bio-tech, Shanghai, China) at a dilution of 1:2,000.
RT-PCR and quantitative real-time RT-PCR (qRT-PCR)
Total RNA was isolated from cultured cells using Trio Reagent (Nitrogen, Carlsbad, CA). RNA (1 lg) was reverse transcribed using M-MLV (Protégé, Madison, WI) and oligo(dT) 18 primer (Sangon, Shanghai, China). RT-PCR was carried out using premix Taq polymerase (Takara, Dalian, China) in a MyCycler Thermal Cycler (Bio-Rad, Hercules, CA). RT-PCR products were fractionated by 1.5% agarose gel electrophoresis, stained with ethidium bromide and photographed using a Chemidoc XRS Gel Documentation System (Bio-Rad, Hercules, CA).
qRT-PCR was carried out in an iCycler iQ Multicolor realtime PCR detection system (Bio-Rad Laboratories, Hercules, CA) using SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA). Primers used were as follows: b-actin:
Serial dilutions of plasmid DNA ranging from 10 8 to 10 3 molecules/ lL for b-actin and 10 7 to 10 2 molecules/lL for human IGFBP-6 were used to generate standard curves. After 3 min incubation at 95 C, amplification was performed as follows: 95 C, 10 s, 60 C, 30 s, for 40 cycles. Each assay for an unknown sample was performed in duplicate along with the standard DNA and negative control. The number of molecules of a particular gene transcript was calculated based on the standard curve and normalized to b-actin mRNA levels.
In vitro capillary-like tube formation assay
The effect of IGFBP-6 on angiogenesis was examined using an in vitro tube formation assay as reported previously. 17 Briefly, aliquots (50 lL) of Matrigel were plated into individual wells of 96 well tissue culture plates and allowed to polymerize at 37 C. After incubation in serum-free medium for 12 h, HUVEC cells were trypsinized and re-suspended in culture medium containing 1% FBS. HUVEC cells (1Â10 4 ) were plated into each well with or without recombinant human IGFBP-6, 11 human VEGF 165 (R&D System, Minneapolis, MN), and/or human pigment epitheliumderived factor (PEDF) (ProSpec-Tany Techno Gene, East Brunswick, NJ). After 12 h incubation, a picture was taken to cover the entire surface area of each well using a phase-contrast microscope. The number of total nodes and tube length were measured. The total node number in the control group (BD Matrigel) is 40-56/well. The results are expressed as a percentage of the control group.
Plasmid construction, capped mRNA synthesis and microinjection
To study the effects of IGFBP-6 on angiogenesis in zebrafish embryos, a DNA fragment containing the open reading frame (ORF) of human IGFBP-6 (with the stop codon deleted) was amplified by RT-PCR (forward primer 5 0 -TTGGATCCGCC ACCATGACCCCCC-3 0 and reverse primer 5 0 -TGCGAAT TCCGCC GCTACTCCCA-3 0 ). The amplified PCR product was digested with EcoR I and BamH I and subcloned into the pCS2-eGFP vector 18 to create pCS2-hIGFBP-6:eGFP. The construct was verified by DNA sequencing. The construction of zebrafish IGFBP-6b expression plasmids was reported recently. 16 Capped mRNA was synthesized using a mMES-SAGE mMACHINE kit (Ambion, Austin, TX).
Microinjection and in vivo angiogenesis assay in zebrafish
To visualize and quantify the effect of IGFBP-6 on angiogenesis in zebrafish embryos, capped mRNA was microinjected into flk1:GFP transgenic zebrafish embryos 19 as reported previously. 15 After injection, embryos were placed in embryorearing solution and kept at 28.5 C. Live embryos were imaged at 24 and 30 hpf. GFP mRNA and phenol red injected embryos were used as controls.
In vivo tumor angiogenesis experiments
Xenografting experiments were performed as described previously.
14 Briefly, empty vector or human IGFBP-6 transfected Rh30 cells (1 Â 10 7 per mouse) were injected subcutaneously into 5-6 week old female athymic BALB/c nude mice. Five control and four IGFBP-6-overexpressing mice were studied. Animal care, feeding, maintenance and surgery have been reported previously.
14 After 27 d, mice were sacrificed. Xenografts were excised and fixed in formalin. Paraffin sections (4 lm) were cut and stained with hematoxylin and eosin. Blood vessels, as defined by erythrocyte-containing luminal structures, were counted in 6-10 fields at 100Â magnification in each tumor.
Statistics
Data are shown as mean 6 standard error (SE). Differences among groups were analyzed by one-way analysis of variance (ANOVA) followed by Fisher's LSD post-hoc test or by unpaired t-test (SPSS, Chicago, IL).
Results
Hypoxia up-regulates IGFBP-6 expression in vascular endothelial cells through HIF-1
To determine the possible effect of hypoxia on IGFBP-6 expression, human umbilical vascular endothelial cells (HUVECs) were subjected to hypoxia (1% O 2 ) treatment for up to 60 h. RNA was isolated and IGFBP-6 mRNA levels were determined by qRT-PCR. As shown in Figure 1a , hypoxia treatment resulted in a significant increase in IGFBP-6 mRNA levels in HUVECs after 48 and 60 h (Fig. 1a) . Next, HUVEC cells were treated with various concentrations of the hypoxia mimetic CoCl 2 . CoCl 2 can activate hypoxia-dependent pathways under normal oxygen levels by stabilizing HIF1a and is often used as a hypoxia mimetic. CoCl 2 significantly increased IGFBP-6 mRNA levels at 100 and 200 lM (Fig. 1b) . Similar induction of IGFBP-6 by hypoxia and CoCl 2 was also observed by RT-PCR in HUVECs and rat brain vessel endothelial cells (Supporting Information Fig.  S1 ). Further analyses showed that hypoxia (12 h) and CoCl 2 (6 h)-treatment markedly increased HIF-1a levels in HUVECs (Fig. 1c) and increased the expression of PDK1 (Supporting Information Fig. S1 ), a well known HIF-1 target gene. [1] [2] [3] Sequence analysis of the human IGFBP-6 promoter suggested that there are eight canonical HREs located in the promoter region of human IGFBP-6 gene: five in the forward orientation and three in the reverse orientation (Fig. 1d) . These results suggest that hypoxia induces the expression of IGFBP-6 in human and rodent vascular endothelial cells (VECs), likely via a HIF-1-mediated mechanism.
IGFBP-6 inhibits angiogenesis through an IGF-independent mechanism in vitro
We next examined the effect of IGFBP-6 on angiogenesis using an in vitro capillary-like tube formation assay. VECs can form blood vessel networks when grown on Matrigel. 17 As shown in Figure 2a , when grown on BD matrigel matrix phenol red free, HUVEC cells formed highly organized capillary-like networks. Addition of IGFBP-6 resulted in fewer and partially formed capillary-like structures (Fig. 2a) . To quantify the IGFBP-6 effect, mean tube length and node number were determined. As shown in Figure 2b , IGFBP-6 significantly decreased tube length at concentrations of 500 ng/mL (61 6 8% of control, p < 0.01) and 1,000 ng/mL (64 6 5% of control, p < 0.05). Similarly, IGFBP-6 significantly decreased node number compared to the control group (Fig.  2c, p < 0.01) .
To determine whether the inhibitory effects of IGFBP-6 on angiogenesis are IGF-independent, we tested the activity of mIGFBP-6, an IGFBP-6 mutant that has at least 10,000-fold lower binding affinity for IGF-II than native IGFBP-6. had essentially the same inhibitory activity as native IGFBP-6. The mean tube length in the presence of 500 ng/mL mIGFBP-6 was 57 6 2% of the control level (p < 0.001) and the node number was 62 6 6% of control (p < 0.01). Similar results were obtained when 1,000 ng/mL mIGFBP-6 was added (Fig. 3) . These in vitro results suggest that IGFBP-6 inhibits angiogenesis through an IGF-independent mechanism.
IGFBP-6 inhibits VEGF-stimulated angiogenesis in vitro
We next investigated the functional relationship between IGFBP-6 and VEGF. As mentioned earlier, hypoxia promotes angiogenesis by inducing angiogenesis-promoting molecules such as VEGF. Human PEDF, which inhibits angiogenesis, was used as a control. As shown in Figure 4 , addition of VEGF 165 resulted in a significant increase in the average tube length and the node number. As expected, PEDF significantly decreased in both parameters (Fig. 4) . PEDF reduced VEGFinduced angiogenesis to or below the basal levels (Fig. 4) . Addition of IGFBP-6 with VEGF 165 also abolished VEGFstimulated angiogenesis. In fact, addition of IGFBP-6 with VEGF 165 significantly reduced the average tube length and node number below control values (Fig. 4) . These results suggest that IGFBP-6 inhibits basal as well as VEGF-stimulated angiogenesis in vitro.
IGFBP-6 inhibits embryonic angiogenesis in vivo and this action is conserved in zebrafish
To test the effect of IGFBP-6 in an in vivo setting, capped mRNA encoding human IGFBP-6 was synthesized and injected into flk1:GFP embryos. The flk1:GFP transgenic zebrafish line is widely used for studying vascular development. In this line, GFP expression, driven by the flk1 gene promoter, is exclusively expressed in vascular epithelial cells in the developing vasculature, 19 thus permitting visualization of the developing blood vessels in vivo (Fig. 5a ). Phenol red was injected as control. As shown in Figure 5a , embryos injected with human IGFBP-6 mRNA had fewer inner segmental vessels (ISV) compared to embryos injected with phenol red or intact embryos (Fig. 5b) . As shown in Figure 5b , the mean relative number of ISVs in the intact control group was 100 6 5% at 30 hpf. A similar value (100 6 3%) was obtained in the phenol red injected group. Injection of GFP mRNA also had no effect (not shown). In contrast, human IGFBP-6 significantly decreased relative ISV number to 54 6 5% of control (p < 0.0001). These results, consistent with the (c) Hypoxia and CoCl 2 treatment increases nuclear HIF-1a levels. HUVECs were subjected to hypoxia (0.1%) for 12 h or 500 lM CoCl 2 for 6 h. The nuclear protein was prepared and analyzed by Western blot using the indicated antibodies. D) Human IGFBP-6 gene has eight canonical HRE and 14 putative HAS sites in the promoter/enhancer region.
in vitro data, suggest that human IGFBP-6 inhibits angiogenesis in this in vivo model.
To determine whether this anti-angiogenic activity is conserved in zebrafish, we prepared capped mRNA for the zebrafish igfbp-6b gene and injected it into flk1:GFP embryos. As shown in Figure 5b , zebrafish IGFBP-6b significantly inhibited embryonic vascular development (37 6 5%, p < 0.001). These results suggest that IGFBP-6 is an anti-angiogenic factor in vivo, and this action is conserved between human and zebrafish IGFBP-6.
IGFBP-6 inhibits rhabdomyosarcoma xenograft angiogenesis
We next investigated the role of IGFBP-6 in tumor angiogenesis by xenografting empty vector-or human IGFBP-6-transfected Rh30 human rhabdomyosarcoma cells into athymic BALB/c nude mice. We previously showed that overexpression of human IGFBP-6 in these tumor cells inhibits cell proliferation and promotes apoptosis in vitro and reduces xenograft growth in vivo.
14 After 27 d, tumor volume of the IGFBP-6-transfected xenografts was 60% lower than that of vector control xenografts (0.34 6 0.08 vs. 0.86 6 0.06 cm 2 , p < 0.05), confirming our previous results.
14 Blood vessel density, as defined by erythrocyte-containing luminal structures per field, was quantified. Vessel density was 52% lower in IGFBP-6-transfected xenografts than in vector control xenografts (4.3 6 0.5 vs. 8.9 6 1.2 vessels/field, p < 0.05, Fig. 6 ), suggesting that IGFBP-6 inhibits tumor angiogenesis in this in vivo model.
Discussion
In this study, we have provided several lines of experimental evidence supporting the notion that IGFBP-6 is an hypoxiainducible gene that plays a negative role in hypoxia-induced tumor angiogenesis. We show that prolonged hypoxia induces IGFBP-6 expression in human and rat VECs, likely via 
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HIF-1 activation. Our in vitro assays, using cultured human HUVECs, and in vivo studies, using flk1:GFP zebrafish embryos, suggest that IGFBP-6 is a potent anti-angiogenic molecule. This action is conserved across species and is IGFindependent. Furthermore, we provide direct evidence for an inhibitory role of IGFBP-6 in tumor angiogenesis in Rh30 human rhabdomyosarcoma xenografts.
VECs are critical components of the vasculature and play a crucial role in the maintenance of vascular integrity. These cells are hypoxia tolerant and can divide under hypoxic conditions. There is a large body of published data suggesting that major components of the IGF signaling pathway are expressed and functional in VECs. 20 IGFs are evolutionarily conserved polypeptides that regulate a wide range of cellular processes including mitogenesis, differentiation, migration and survival. 21 These actions are largely mediated through the IGF-I receptor (IGF-IR), a receptor tyrosine kinase. Ligand binding of the IGF-IR activates a number of major signaling pathways, including the Ras-MAPK and the PI3 kinase-Akt pathways. IGF signaling has been implicated in hypoxia-induced tumor angiogenesis. 20 IGF-I stimulates HIF-1a expression in endothelial cells via the PI3 kinase/ mTOR signaling pathway. 22 IGF-I also stimulates VEGF expression and secretion via HIF-1-dependent and -independent mechanisms. 23 Furthermore, pharmacological blockade or tissue-specific knockout of the IGF-IR decreased retinal neovascularization. 24, 25 Cultured mammalian VECs express IGFBP 2-6. 12, 26, 27 IGFBPs synthesized by VECs are involved in transfer of IGFs across the VEC barrier. 28, 29 IGFBPs bind IGFs and inhibit or potentiate their actions in the vasculature. 20 Han and coworkers have shown that IGFBP-6 mRNA expression was very low in cultured bovine VECs and increased with exposure to hypoxia. 12 The mechanism underlying this hypoxia induction, however, was not studied. In this study, we have extended this observation to human and rat VECs, suggesting the up-regulation of IGFBP-6 expression in VECs is conserved across species. Furthermore, we provide evidence that HIF-1 activation is likely involved in hypoxia-induced IGFBP-6 gene expression. Hypoxia or CoCl 2 treatments increased nuclear HIF-1a levels and increased expression of established HIF-1 target genes such as PDK1. Sequence analysis of the human IGFBP-6 gene showed that there are eight canonical HREs located in the promoter region: five in the forward orientation and three in the reverse orientation. It has been proposed that cooperative interactions between the HRE and an adjacent HIF-1 ancillary sequence (HAS) are critical to confer hypoxia responsiveness. 15 In the promoter region of human IGFBP-6, we found 14 putative HAS, six in the forward orientation and eight in the reverse orientation. HIF-1 has also been shown to induce the expression of a related gene, IGFBP-1, and hypoxia increased IGFBP-1 expression in the liver through an HRE located in intron 2 of its gene. 30 More recent studies show that the induction of IGFBP-1 gene expression by hypoxia is mediated through HIF-1 both in vitro and in vivo. 15 There is a clear temporal 
difference between IGFBP-1 and IGFBP-6 regulation by hypoxia: hypoxia increases IGFBP-1 gene expression rapidly in liver/hepatocytes, whereas the up-regulation of the IGFBP-6 gene was not observed until 48 h of hypoxia. This timing is interesting as it implies that IGFBP-6 induction by hypoxia may act as a negative feedback mechanism in hypoxiainduced angiogenesis. A number of mechanisms underlying the inhibitory actions of IGFBP-6 on tumor growth have been suggested. IGFBP-6 has been shown to inhibit tumor cell proliferation and increase apoptosis, most likely by binding to and inhibiting IGF-II actions.
10,11,14 IGFBP-6 has been recently reported to interact with Ku80, a DNA-end binding protein, in the cytoplasm to regulate cell survival, and this effect may be IGF-dependent. 31 IGFBP-6 acts as an effector of the tumor suppressor gene semaphorin 3B in lung cancer cells, although IGF-II partially abrogated its effects. 32 A number of recent studies also indicate that IGFBP-6 may suppress tumor growth via IGF-independent actions. IGFBP-6 has a functional nuclear localization signal and is capable of translocation to the nucleus in an IGF-independent manner. 33 IGFBP-6 inhibited nasopharyngeal carcinoma cell proliferation, invasion and metastasis by directly binding to the promoter of the tumor suppressor EGR-1 and increasing its expression; IGF-dependence of this effect was not directly studied. 34 In contrast to the above studies, IGFBP-6 has also been shown to promote rhabdomyosarcoma and colon cancer cell migration via p38 MAPK and crosstalk with other MAPKs in an IGF-independent manner. 11, 35 The results of our study suggest an additional and novel mechanism by which IGFBP-6 inhibits tumor growth. Our in vitro and in vivo data show that IGFBP-6 is a potent angiogenesis inhibitor. This action is IGF-independent and is evolutionarily conserved in human and fish. Ongoing solid tumor growth requires angiogenesis which is driven by relative hypoxia. 36 Inhibition of hypoxia-induced angiogenesis by IGFBP-6 may, therefore, contribute to its tumor suppressor properties. There are several plausible mechanisms by which IGFBP-6 inhibits angiogenesis: (i) since IGFBP-6 suppresses VEGF-induced tube formation when added together in cultured HUVECs, IGFBP-6 may inhibit VEGF action by directly binding to VEGF itself and/or affect VEGF receptormediated signaling; (ii) IGFBP-6 has been shown to activate p38 MAPK in an IGF-independent manner and this is required for its ability to promote rhabdomyosarcoma and colon cancer cell migration. 35 It is possible that IGFBP-6 inhibits angiogenesis via a similar mechanism; (iii) IGFBP-6 has a functional nuclear localization signal and is capable of translocation to the nucleus. 33 A recent study reports that IGFBP-6 inhibits nasopharyngeal carcinoma cell proliferation, invasion and metastasis by directly binding to the promoter of the tumor suppressor gene EGR-1 and increasing its expression. 34 The possible involvement of nuclear IGFBP-6 in the anti-angiogenic action cannot be ruled out. Future studies aimed at elucidating the molecular basis of IGF-independent inhibition of angiogenesis by IGFBP-6 should deepen our understanding of hypoxia-regulated tumor angiogenesis. It should be pointed out that our current model on the hypoxia-induced IGFBP-6 expression in VECs and the anti-angiogenic action of IGFBP-6 is based on results from gain-of-functional experiments, either by adding large amounts of purified IGFBP-6 to cultured human cells in vitro or by overexpressing IGFBP-6 in animal tissues in vivo. Future studies are needed to determine whether the local levels of IGFBP-6 in tumor vasculature are sufficiently high to cause a significant decrease in angiogenesis in vivo. It will also be interesting to test whether knockdown of IGFBP-6 in VECs using short double-stranded RNA (siRNA) will enhance hypoxia-induced angiogenesis and increase tumor growth. Moreover, tissue-specific IGFBP-6 knockout mouse lines will be needed to determine the physiological role of the hypoxia-induced IGFBP-6 expression by VECs in vivo. Understanding the signaling pathways leading to the negative regulation of angiogenesis will likely provide important tools to develop novel therapeutic strategies to hinder deregulated tumor angiogenesis.
